Securing Europe’s Health Sovereignty: From Innovation to Outcomes
Health sovereignty today is not defined by physical control alone: stockpiles, warehouses or emergency reserves. Those still matter, but the
Read more
Industry
The role of vaccines innovation in Europe’s biotech strategy
A sector already delivering for Europe Europe remains one of the world’s leading vaccine development and manufac turing ecosystems and
Read more
Europe’s Unused Power
Europe has the makings of a biopharmaceutical superpower and behaves as if it did not. The science is here, the
Read more
EU pharmaceutical policy at a crossroads: A call to EU Institutions and Member States to concretely act now
The role of the European Union (EU) in defining healthcare policy has become more prominent after the outbreak of the
Read more
Bridging the gap between advanced therapy development and patient access in Europe: regulatory, clinical and translational challenges
Europe’s ambition to secure health sovereignty through global leadership in advanced therapies is now a central policy priority—both timely and
Read more
Innovation and Access to Medicines in Europe’s Biotech Framework
The European Biotech Act represents one of the most significant attempts in recent years to strengthen Europe’s position in biotechnology
Read more
Building a competitive and sustainable biotech ecosystem in Europe
Does Europe still have a realistic chance of remaining competitive with the United States and China in biotechnology—and under what
Read more
Strengthening Europe’s pharmaceutical sovereignty.
Across the European Union, 2023 and 2024 saw record levels of medicine shortages reported, with 136 medicines running critically short
Read more